Transaction · 0001193125-26-417919

Ceesay Abraham

Ceesay Abraham, CEO, reported an open-market or private sale at Rapport Therapeutics, Inc. involving 1147.000000 shares for an estimated $35167.02. Reported holdings after the transaction were 452245.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCEO
RAPPRapport Therapeutics, Inc.
Filing timeOct 08
Trade dateOct 07, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded0.25%Shares sold ÷ (holdings after + shares sold). Estimated position before: 453,392 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$30.86
Pre-filing
1mo ago +48.3%1w ago +8.9%1d ago +0.9%
Returns since
7d30d90d180d1y

RAPP price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
RAPP since 2026-10-08Filed today · pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-417919
Common Stock
Transaction date
Oct 07, 2026
Filed Oct 08, 2026, 08:07 PM · 1d delay
Shares
1.14k sh
$30.66 per share
Estimated value
-$35.1k
Computed from shares × price
Holdings after
452k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026.

  2. F2

    The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide…

  3. F3

    The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide…

Original filing · 0001193125-26-417919
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

RAPP